Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 29 | 2021 | 78 | 9.600 |
Why?
|
| Antiviral Agents | 32 | 2021 | 132 | 8.250 |
Why?
|
| Hepatitis C | 20 | 2022 | 65 | 7.280 |
Why?
|
| Liver Diseases | 14 | 2022 | 41 | 6.490 |
Why?
|
| Hepacivirus | 23 | 2022 | 73 | 4.900 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 52 | 4.250 |
Why?
|
| Liver Transplantation | 9 | 2023 | 79 | 4.170 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 7 | 2.360 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 30 | 2.040 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 60 | 1.980 |
Why?
|
| Pregnancy | 13 | 2022 | 403 | 1.840 |
Why?
|
| Ribavirin | 9 | 2016 | 32 | 1.800 |
Why?
|
| Humans | 71 | 2024 | 29337 | 1.690 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 19 | 1.650 |
Why?
|
| Coinfection | 4 | 2023 | 29 | 1.400 |
Why?
|
| Sulfonamides | 7 | 2020 | 54 | 1.330 |
Why?
|
| Hepatitis B | 5 | 2019 | 19 | 1.300 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 103 | 1.270 |
Why?
|
| Interferon-alpha | 5 | 2012 | 66 | 1.270 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 55 | 1.260 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 32 | 1.230 |
Why?
|
| United States | 19 | 2022 | 2333 | 1.230 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 10 | 1.140 |
Why?
|
| Female | 37 | 2024 | 16197 | 1.140 |
Why?
|
| HIV Infections | 4 | 2021 | 970 | 1.060 |
Why?
|
| Carbamates | 9 | 2020 | 12 | 1.040 |
Why?
|
| Societies, Medical | 3 | 2022 | 190 | 1.020 |
Why?
|
| Quinoxalines | 5 | 2020 | 11 | 0.980 |
Why?
|
| Drug Therapy, Combination | 13 | 2021 | 241 | 0.960 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.950 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3478 | 0.900 |
Why?
|
| Gastroenterology | 3 | 2017 | 11 | 0.860 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 45 | 0.840 |
Why?
|
| Living Donors | 1 | 2021 | 8 | 0.820 |
Why?
|
| Prejudice | 1 | 2021 | 38 | 0.810 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 30 | 0.750 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 24 | 0.750 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 43 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 132 | 0.750 |
Why?
|
| Benzimidazoles | 3 | 2019 | 12 | 0.740 |
Why?
|
| Patient Selection | 1 | 2021 | 232 | 0.730 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 125 | 0.720 |
Why?
|
| Genotype | 10 | 2017 | 405 | 0.710 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.700 |
Why?
|
| Sofosbuvir | 6 | 2019 | 7 | 0.670 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 7 | 0.670 |
Why?
|
| Viral Load | 5 | 2016 | 197 | 0.670 |
Why?
|
| Obesity | 1 | 2021 | 291 | 0.670 |
Why?
|
| Adult | 21 | 2021 | 8601 | 0.660 |
Why?
|
| Algorithms | 2 | 2020 | 400 | 0.660 |
Why?
|
| Fear | 1 | 2018 | 47 | 0.640 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 6 | 0.640 |
Why?
|
| Liver | 3 | 2022 | 173 | 0.620 |
Why?
|
| Drugs, Generic | 1 | 2016 | 4 | 0.580 |
Why?
|
| Cyclopropanes | 5 | 2020 | 25 | 0.580 |
Why?
|
| Middle Aged | 21 | 2021 | 9823 | 0.580 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.570 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 13 | 0.570 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 2 | 0.570 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 8 | 0.560 |
Why?
|
| Virology | 1 | 2015 | 14 | 0.550 |
Why?
|
| Length of Stay | 2 | 2016 | 317 | 0.510 |
Why?
|
| Liver Function Tests | 3 | 2022 | 24 | 0.510 |
Why?
|
| Young Adult | 9 | 2021 | 1932 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2016 | 123 | 0.500 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 379 | 0.480 |
Why?
|
| Mass Screening | 5 | 2021 | 177 | 0.470 |
Why?
|
| Prevalence | 3 | 2023 | 487 | 0.470 |
Why?
|
| Preventive Health Services | 1 | 2013 | 15 | 0.460 |
Why?
|
| Male | 23 | 2021 | 15621 | 0.460 |
Why?
|
| Advisory Committees | 1 | 2013 | 34 | 0.460 |
Why?
|
| Prognosis | 5 | 2022 | 840 | 0.460 |
Why?
|
| Heart Failure | 1 | 2016 | 202 | 0.460 |
Why?
|
| Risk Factors | 6 | 2023 | 2443 | 0.450 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 41 | 0.450 |
Why?
|
| Health Policy | 1 | 2013 | 50 | 0.450 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3273 | 0.440 |
Why?
|
| Disease Management | 2 | 2016 | 114 | 0.430 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 7 | 0.420 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 10 | 0.390 |
Why?
|
| Proline | 4 | 2019 | 19 | 0.390 |
Why?
|
| Imidazoles | 4 | 2020 | 72 | 0.380 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 251 | 0.380 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 5 | 0.370 |
Why?
|
| RNA, Viral | 4 | 2022 | 148 | 0.370 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 20 | 0.370 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 37 | 0.360 |
Why?
|
| Aged | 14 | 2020 | 9448 | 0.340 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 223 | 0.330 |
Why?
|
| Cost of Illness | 2 | 2023 | 54 | 0.330 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.320 |
Why?
|
| Motivation | 3 | 2023 | 100 | 0.320 |
Why?
|
| Fatty Liver | 2 | 2019 | 30 | 0.310 |
Why?
|
| Cohort Studies | 6 | 2021 | 1939 | 0.310 |
Why?
|
| Anemia | 1 | 2008 | 97 | 0.300 |
Why?
|
| Medication Adherence | 2 | 2019 | 78 | 0.300 |
Why?
|
| Benzofurans | 3 | 2020 | 7 | 0.270 |
Why?
|
| Adolescent | 4 | 2020 | 2279 | 0.270 |
Why?
|
| Graft Rejection | 2 | 2018 | 76 | 0.260 |
Why?
|
| Valine | 4 | 2019 | 11 | 0.260 |
Why?
|
| Drug Interactions | 2 | 2015 | 67 | 0.250 |
Why?
|
| Incidence | 2 | 2020 | 756 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 144 | 0.240 |
Why?
|
| Pyrrolidines | 3 | 2018 | 21 | 0.240 |
Why?
|
| Risk Assessment | 3 | 2018 | 679 | 0.240 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.240 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 10 | 0.240 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 7 | 0.240 |
Why?
|
| Prospective Studies | 4 | 2019 | 1811 | 0.240 |
Why?
|
| Amides | 2 | 2020 | 21 | 0.230 |
Why?
|
| Benzamides | 1 | 2023 | 16 | 0.230 |
Why?
|
| Uracil | 3 | 2019 | 5 | 0.230 |
Why?
|
| Vaccination | 1 | 2023 | 41 | 0.230 |
Why?
|
| Ritonavir | 3 | 2019 | 18 | 0.230 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.220 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 5 | 0.220 |
Why?
|
| RNA | 1 | 2022 | 39 | 0.220 |
Why?
|
| Chronic Disease | 3 | 2020 | 495 | 0.220 |
Why?
|
| Fibrosis | 1 | 2022 | 39 | 0.220 |
Why?
|
| History, 20th Century | 1 | 2022 | 84 | 0.210 |
Why?
|
| Selection Bias | 1 | 2021 | 10 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 4851 | 0.210 |
Why?
|
| Fertility | 1 | 2021 | 20 | 0.210 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 4 | 0.200 |
Why?
|
| Graft Survival | 2 | 2019 | 98 | 0.200 |
Why?
|
| Leucine | 2 | 2018 | 15 | 0.200 |
Why?
|
| World Health Organization | 1 | 2020 | 18 | 0.200 |
Why?
|
| Tissue Donors | 1 | 2021 | 74 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 13 | 0.190 |
Why?
|
| Anilides | 2 | 2019 | 10 | 0.190 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 4 | 0.190 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 148 | 0.190 |
Why?
|
| Recurrence | 2 | 2011 | 350 | 0.190 |
Why?
|
| Pandemics | 1 | 2022 | 236 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2020 | 75 | 0.190 |
Why?
|
| Critical Care | 1 | 2022 | 234 | 0.180 |
Why?
|
| Consensus | 2 | 2021 | 105 | 0.180 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 8 | 0.180 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.180 |
Why?
|
| Forecasting | 1 | 2019 | 117 | 0.180 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 70 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2019 | 81 | 0.170 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1830 | 0.170 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.170 |
Why?
|
| Internationality | 1 | 2018 | 24 | 0.170 |
Why?
|
| Logistic Models | 2 | 2010 | 407 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 333 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2019 | 604 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 437 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2017 | 21 | 0.150 |
Why?
|
| Time Factors | 3 | 2016 | 1616 | 0.150 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 2 | 0.150 |
Why?
|
| Psychometrics | 1 | 2018 | 262 | 0.150 |
Why?
|
| Patient Participation | 1 | 2017 | 52 | 0.140 |
Why?
|
| Commerce | 1 | 2016 | 13 | 0.140 |
Why?
|
| Canada | 1 | 2016 | 56 | 0.140 |
Why?
|
| Ascites | 1 | 2016 | 5 | 0.140 |
Why?
|
| Safety | 1 | 2016 | 45 | 0.140 |
Why?
|
| Quality Control | 1 | 2016 | 43 | 0.140 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fraud | 1 | 2016 | 21 | 0.140 |
Why?
|
| Interferons | 1 | 2016 | 13 | 0.140 |
Why?
|
| Eclampsia | 1 | 2016 | 2 | 0.140 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 8 | 0.140 |
Why?
|
| Drug Approval | 1 | 2016 | 30 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1184 | 0.140 |
Why?
|
| Hospitalization | 2 | 2016 | 317 | 0.140 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 148 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1113 | 0.140 |
Why?
|
| Directive Counseling | 1 | 2015 | 12 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 38 | 0.140 |
Why?
|
| Benchmarking | 1 | 2015 | 41 | 0.130 |
Why?
|
| Isoquinolines | 1 | 2015 | 14 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2015 | 140 | 0.130 |
Why?
|
| Benzazepines | 1 | 2015 | 8 | 0.130 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Comorbidity | 4 | 2018 | 498 | 0.130 |
Why?
|
| Liver Failure | 1 | 2015 | 11 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2017 | 159 | 0.130 |
Why?
|
| Indoles | 1 | 2015 | 48 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 161 | 0.130 |
Why?
|
| Zinc | 1 | 2015 | 35 | 0.130 |
Why?
|
| Phenotype | 1 | 2015 | 355 | 0.130 |
Why?
|
| Hospitalists | 1 | 2014 | 5 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 340 | 0.120 |
Why?
|
| Off-Label Use | 1 | 2014 | 7 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 324 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2014 | 70 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 87 | 0.120 |
Why?
|
| Drug Eruptions | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 14 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 211 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 9 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2014 | 138 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 43 | 0.110 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 2 | 0.110 |
Why?
|
| Drug Combinations | 3 | 2017 | 82 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 521 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2010 | 8 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 23 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 218 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 161 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 132 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 285 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 553 | 0.090 |
Why?
|
| Fluorenes | 2 | 2019 | 3 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2008 | 81 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 324 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 959 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 68 | 0.060 |
Why?
|
| Pyrroles | 1 | 2022 | 17 | 0.060 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 2 | 0.060 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 2 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 8 | 0.060 |
Why?
|
| Hypoxia | 1 | 2022 | 60 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 44 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 12 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 15 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 34 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 169 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 23 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 188 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 37 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 662 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 2 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 105 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 26 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 52 | 0.040 |
Why?
|
| Serine Proteases | 1 | 2016 | 6 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2018 | 140 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2016 | 32 | 0.040 |
Why?
|
| Career Choice | 1 | 2016 | 30 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 62 | 0.040 |
Why?
|
| Pain Management | 1 | 2018 | 143 | 0.040 |
Why?
|
| Cost Savings | 1 | 2016 | 36 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 39 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 140 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 155 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 141 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 788 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 65 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 138 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 162 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 330 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 230 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 254 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 28 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 349 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 67 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 90 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 141 | 0.030 |
Why?
|
| Immunoassay | 1 | 2012 | 41 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 65 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 787 | 0.030 |
Why?
|
| Probability | 1 | 2012 | 94 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 132 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 957 | 0.020 |
Why?
|